Low dose of sublingual immunotherapy in patients with allergic rhinitis in a randomized double-blind placebocontrolled study

Background: Few placebo controlled studies for sublingual immunotherapy (SLIT) have been performed so far in Latin America, and some issues like treatment scheme and doses remain uncertain Objective: to asses improvement in nasal, pharyngeal and ocular symptoms with low doses of SLIT to Dermatophago...

Descripción completa

Detalles Bibliográficos
Autores principales: Leal Villarreal, Lucía, Huerta López, José G., Salinas Carmona, Mario César, Cárdenas Estrada, Eloy, Muñoz Espinosa, Linda Elsa, Castro Corona, María de los Ángeles, Medina de la Garza, Carlos Eduardo
Formato: Artículo
Lenguaje:inglés
Publicado: Elsevier 2010
Materias:
Acceso en línea:http://eprints.uanl.mx/4444/1/2010-Alergias-Sublingual-V12-N46-DrECE.pdf
Descripción
Sumario:Background: Few placebo controlled studies for sublingual immunotherapy (SLIT) have been performed so far in Latin America, and some issues like treatment scheme and doses remain uncertain Objective: to asses improvement in nasal, pharyngeal and ocular symptoms with low doses of SLIT to Dermatophagoides pteronyssinus comparing it with a placebo, in a Mexican population with allergic rhinitis (AR). Methods: a prospective, double-blind placebo-controlled, randomized study, with 32, patients with chronic, moderate to severe AR; 16 patients were treated with SLIT and 16 with placebo for 6 months with a total dose of D. pteronyssinus (Der p1) of 50.4 mcg. Nasal, pharyngeal and ocular symptoms were monitored using a symptoms diary to evaluate the degree of improvement and reduction in the use of medication. Results: Significant lower symptom and drug scores were found in SLIT group where 85% of patients showed clinical improvement. On the placebo group, 24% of patients improved and 76% had no response or worsened; 94% of patients on SLIT required less symptomatic medication compared with the placebo group. There was a reduction in positivity to cutaneous test to D. pteronyssinus in 50% of the patients on SLIT, whereas placebo patients remained all positive